Carter Bankshares Q2 2026: $1.31 EPS, NPLs Plunge After Loan Sale, $500M Lawsuit Disclosed
CARE has more than doubled off its 52-week low of $16.78.
Summary
Carter Bankshares reported Q2 2026 EPS of $1.31, far above the $0.76 consensus, as gains from strategic transactions and a cleaner balance sheet drove results. The filing also reveals a $500 million lawsuit related to the loan sale that transformed the bank's credit profile.
Key Events · Earnings and Guidance · CARE
-
Q2 Earnings Beat
Net income reached $28.9M, or $1.31 per diluted share, compared to $8.5M, or $0.37 per share, in Q2 2025. The quarter included a $35.9M pre-tax gain on the sale of the insurance business and a $12.5M pre-tax loss on a securities portfolio repositioning.
-
Balance Sheet Transformation
Nonperforming loans fell to $37.6M (1.01% of portfolio loans) from $244.0M (6.29%) at year-end 2025, primarily due to the first-quarter loan sale. The allowance for credit losses declined to $55.2M (1.48% of loans) from $71.5M (1.84%). All FHLB borrowings were repaid.
-
$500M Lawsuit Disclosed
The borrowers whose loans were sold in the first quarter filed a lawsuit seeking at least $500M in damages and rescission of the sale. The company denies the allegations and intends to defend vigorously, but no loss estimate can be made at this early stage.
-
Net Interest Margin Expansion
Net interest income rose 23.5% to $40.0M, with net interest margin expanding 58 basis points to 3.38%, driven by higher asset yields and lower funding costs.
Analysis · CARE · Finance
A standout second quarter saw Carter Bankshares deliver EPS of $1.31, fueled by a $35.9M gain on the sale of its insurance business and a notable expansion in net interest margin. The balance-sheet transformation is the real headline: nonperforming loans collapsed from $244M to $37.6M following the first-quarter loan sale, and all FHLB borrowings were repaid. Yet the 10-Q also discloses a $500 million lawsuit filed by the borrowers whose loans were sold, seeking to rescind the sale and claiming damages. While the company denies the allegations and intends to defend vigorously, the suit introduces significant legal uncertainty at a time when the bank is otherwise showing its strongest financial position in years.
At the time of this filing, CARE was trading at $34.39 on NASDAQ in the Finance sector, with a market capitalization of approximately $762.2M. The 52-week trading range was $16.78 to $36.06. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.